Levagen+ is safe and effective for reducing discomfort and duration of migraines in healthy adults, according to a recent study funded by the ingredient's supplier, Gencor Pacific.
A new study suggests that Gencor Pacific’s Levagen+ Palmitoylethanolamide (PEA) ingredient may alleviate symptoms of seasonal allergies as shown by a reduction in histamine and inflammatory markers despite a strong placebo effect.
Palmitoylethanolamide (PEA) reduces sensitivity to pain in the central and peripheral nervous systems and increases pain modulation, says a recent study from Austrian researchers.
Palmitoylethanolamide (PEA) may reduce inflammation and optimise immune responses to infectious conditions such as Covid-19, according to researchers in the USA.
Palmitoylethanolamide (PEA) is a safer and more pervasive therapeutic alternative to cannabidiol, say the authors of the Gencor Pacific-commissioned review, ‘Palmitoylethanolamide: A Potential Alternative to Cannabidiol.’
Eight weeks of supplementation with palmitoylethanolamide, an endocannabinoid-like molecule, may improve sleep measures in healthy adults, according to results of a double-blind, randomized, placebo-controlled study.
